We are live on ! Find out more

Tiziana Life Sciences

TLSA

Market cap $102M

0.8000 USD

-0.1047

11.57%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

0.8200

+0.0200

2.5%

1 day

-11.57%

5 days

-15.79%

1 month

-27.93%

3 months

-17.53%

6 months

-37.5%

Year to date

-50%

1 year

-56.52%

5 years

-50.92%

10 years

-52.1%

About: Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Employees: 10

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 42.9%

Neutral 57.1%

Negative 0%

Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto

BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that members of its management and business development team will attend the 10th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting, known as MSToronto2026, being held October 21–23, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.

Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto

Proactive Investors

Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient has begun dosing in its Phase 2 trial of intranasal foralumab in early or mild Alzheimer's disease, with topline data expected in the first quarter of 2027. The milestone completes enrollment and dosing initiation for all participants in the randomized, placebo-controlled study, the biotechnology company said.

Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab

Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease

BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the last patient has begun dosing in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in patients with early/mild Alzheimer's disease (AD). Topline data are anticipated to be announced in Q1 2027.

Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease

Proactive Investors

Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the US Food and Drug Administration to grant orphan drug designation to its intranasal foralumab for multiple system atrophy (MSA), a rare neurodegenerative disease with no approved disease-modifying therapies. MSA is a rapidly progressive disorder that affects autonomic functions such as blood pressure and bladder control, as well as motor control, leading to severe disability and shortened life expectancy.

Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy

Proactive Investors

Tiziana doses first three patients in ALS trial of nasal antibody foralumab

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the first three participants have received their first dose of intranasal foralumab in a Phase 2a trial in people living with amyotrophic lateral sclerosis (ALS). The Healey ALS MyMatch BANYAN trial is testing foralumab, a fully human anti-CD3 monoclonal antibody, delivered as a nasal spray.

Tiziana doses first three patients in ALS trial of nasal antibody foralumab

Proactive Investors

Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Monday the last patient has completed their final visit in the company's Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS). The randomized, double-blind, placebo-controlled INFORM-MS trial enrolled 48 patients across three cohorts at multiple leading U.S.

Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial

Proactive Investors

Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases to study its intranasal foralumab in combination with anti-CD20 therapy for multiple sclerosis patients. The planned trial will target relapsing-remitting multiple sclerosis (RRMS) patients who respond poorly to anti-CD20 therapy alone, a shortfall that may stem from untreated neuroinflammation.

Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial

Proactive Investors

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a potential leading treatment for neurodegenerative disease. The clinical-stage company is developing foralumab, an anti-CD3 antibody delivered via nasal spray, to stimulate regulatory T-cell (Treg) production and reduce the inflammatory processes that drive neurodegeneration.

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

Proactive Investors

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday. The presentation, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial,” is scheduled for 4:30 pm to 6:30 pm Eastern Time during the Scientific Poster Session.

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a poster, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial,” will be presented by Dr. Pinar Uysal today, Monday, August 24, 2026, from 4:30–6:30 p.m. ET during the Scientific Poster Session in the Nexus Pavilion at the Hyatt Regency Grand Cypress Resort in Orlando, Florida.

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

See News Rankings

Price charts implemented using Lightweight Charts™